82_FR_32320 82 FR 32188 - Sunshine Act Meeting: Board of Scientific Counselors NCEH/ATSDR; Cancelation

82 FR 32188 - Sunshine Act Meeting: Board of Scientific Counselors NCEH/ATSDR; Cancelation

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Federal Register Volume 82, Issue 132 (July 12, 2017)

Page Range32188-32188
FR Document2017-14745

Federal Register, Volume 82 Issue 132 (Wednesday, July 12, 2017) 
[Federal Register Volume 82, Number 132 (Wednesday, July 12, 2017)]
[Notices]
[Page 32188]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-14745]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Sunshine Act Meeting: Board of Scientific Counselors NCEH/ATSDR; 
Cancelation

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: The original 
Federal Register Notice for this meeting was published in the Federal 
Register on May 22, 2017, Volume 82, Number 2017-10333, page/s/23250-
23251.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 9:00 a.m.-noon, EDT, 
June 23, 2017.

CHANGES IN THE MEETING: This meeting is being canceled in its entirety.

CONTACT PERSON FOR MORE INFORMATION: Amanda Malasky, BS, ORISE Fellow, 
CDC, 4770 Buford Hwy., Atlanta, GA 30344, telephone 770-488-7699; 
[email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 2017-14745 Filed 7-10-17; 4:15 pm]
 BILLING CODE 4163-18-P

32188 Federal Register / Vol. 82, No. 132 / Wednesday, July 12, 2017 / Notices increasing the probability that information by or to anyone who is not management activities, for both the customers would pay higher prices for an authorized individual. The proposed Centers for Disease Control and fibre channel switches and that Order also incorporates by reference Prevention and the Agency for Toxic innovation would be lessened. non-disclosure provisions contained in Substances and Disease Registry. four prior private Confidentiality Entry Claudette Grant, Agreements that Broadcom, or its Entry into the worldwide fibre predecessor, signed with Cisco. Acting Director, Management Analysis and channel switch market is not likely to To ensure compliance with the Services Office, Centers for Disease Control occur in a timely, likely, or sufficient proposed Order, the Commission will and Prevention. magnitude, character and scope to deter appoint a Monitor to oversee [FR Doc. 2017–14745 Filed 7–10–17; 4:15 pm] or counteract any anticompetitive Broadcom’s and Brocade’s performance BILLING CODE 4163–18–P effects created by the proposed of their obligations pursuant to the Acquisition. Entry is unlikely in light of Consent Agreement. The Monitor will slowly declining demand for fibre be appointed to a five-year term, but the DEPARTMENT OF HEALTH AND channel switches in a mature market, Commission may extend or modify the HUMAN SERVICES customers that tend to stay with one term as appropriate up to a ten-year fibre channel switch manufacturer for period. Further, the Consent Agreement Food and Drug Administration extended periods of time, and the contains appropriate reporting significant capital costs required for requirements. [Docket No. FDA–2017–N–0002] entry. Opportunity for Public Comment New Animal Drugs; Withdrawal of The Consent Agreement The purpose of this analysis is to Approval of a New Animal Drug To remedy the alleged competitive facilitate public comment on the Application concern stemming from Broadcom’s proposed Consent Agreement to aid the access to Cisco’s competitively sensitive Commission in determining whether it AGENCY: Food and Drug Administration, confidential information, the consent should make the proposed Consent HHS. decree prevents the Cisco information Agreement final. This analysis is not an from being shared among Broadcom official interpretation of the proposed ACTION: Notice of withdrawal. employees who could use such Consent Agreement and does not information to raise prices or lessen modify its terms in any way. SUMMARY: The Food and Drug innovation. Administration (FDA) is withdrawing Pursuant to the proposed Order, only By direction of the Commission. approval of two new animal drug authorized individuals will have access Donald S. Clark, applications (NADAs). This action is to Cisco’s competitively sensitive Secretary. being taken at the sponsor’s request confidential information that is given to [FR Doc. 2017–14536 Filed 7–11–17; 8:45 am] because these products are no longer the firewalled entity, which is defined BILLING CODE 6750–01–P manufactured or marketed. as Broadcom’s business group responsible for the development, DATES: Withdrawal of approval is production, sale, and marketing of fibre DEPARTMENT OF HEALTH AND effective July 24, 2017. channel ASICs for Cisco. The firewalled HUMAN SERVICES FOR FURTHER INFORMATION CONTACT: entity will have separate facilities and a Sujaya Dessai, Center for Veterinary separate information technology system Centers for Disease Control and Medicine (HFV–212), Food and Drug with security protocols assuring access Prevention Administration, 7519 Standish Pl., only to the authorized individuals. Sunshine Act Meeting: Board of Rockville, MD 20855, 240–402–5761, Furthermore, Broadcom shall require all Scientific Counselors NCEH/ATSDR; sujaya.dessai@fda.hhs.gov. authorized individuals to sign a non- disclosure agreement, requiring Cancelation SUPPLEMENTARY INFORMATION: Zoetis, compliance with the terms of the Inc., 333 Portage St., Kalamazoo, MI FEDERAL REGISTER CITATION OF PREVIOUS proposed Order. Additionally, the 49007 has requested that FDA withdraw ANNOUNCEMENT: The original Federal proposed Order provides for a cooling approval of NADA 065–291 for bulk off period whereby any authorized Register Notice for this meeting was dihydrostreptomycin sulfate and NADA individual who leaves his or her published in the Federal Register on 065–324 for bulk streptomycin sulfate position at the firewalled entity will not May 22, 2017, Volume 82, Number because the products are no longer work in the development, production, 2017–10333, page/s/23250–23251. manufactured or marketed. sale, or marketing of fibre channel PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 9:00 a.m.–noon, EDT, June Therefore, under authority delegated ASICs for Brocade’s business unit or in 23, 2017. to the Commissioner of Food and Drugs, the development, production, sales, and CHANGES IN THE MEETING: This meeting is and in accordance with § 514.116 Notice marketing of fibre channel switches for being canceled in its entirety. of withdrawal of approval of application twelve months. The proposed Order also requires (21 CFR 514.116), notice is given that CONTACT PERSON FOR MORE INFORMATION: approval of NADA 065–291 and NADA asabaliauskas on DSKBBXCHB2PROD with NOTICES Broadcom to use Cisco’s competitively Amanda Malasky, BS, ORISE Fellow, sensitive confidential information only 065–324, and all supplements and CDC, 4770 Buford Hwy., Atlanta, GA in furtherance of the design, 30344, telephone 770–488–7699; yoo0@ amendments thereto, is hereby manufacturing, and sale of fibre channel cdc.gov. withdrawn, effective July 24, 2017. ASICs for Cisco. Moreover, Broadcom The Director, Management Analysis As neither of these NADAs was will be required to take all actions and Services Office, has been delegated codified, the animal drug regulations do necessary to prevent access to, or the the authority to sign Federal Register not require amendment to reflect the disclosure or use of Cisco’s notices pertaining to announcements of voluntary withdrawal of approval of competitively sensitive confidential meetings and other committee these applications. VerDate Sep<11>2014 17:54 Jul 11, 2017 Jkt 241001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\12JYN1.SGM 12JYN1


Document Created: 2017-07-12 03:00:12
Document Modified: 2017-07-12 03:00:12
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
FR Citation82 FR 32188 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR